Resolvin D1 improves airway inflammation and exercise capacity in cystic fibrosis lung disease

Mucus plugging and non-resolving inflammation are inherent features of cystic fibrosis (CF) that may lead to progressive lung disease and exercise intolerance, which are the main causes of morbidity and mortality for people with CF. Therefore, understanding the influence of mucus on basic mechanisms underlying the inflammatory response and identifying strategies to resolve mucus-driven airway inflammation and consequent morbidity in CF are of wide interest. Here, we investigated the effects of the proresolving lipid mediator resolvin (Rv) D1 on mucus-related inflammation as a proof-of-concept to alleviate the burden of lung disease and restore exercise intolerance in CF. We tested the effects of RvD1 on inflammatory responses of human organotypic airways and leukocytes to CF mucus and of humanized mice expressing the epithelial Na + channel (

• Ferri, G.
• Serano, M.
• Isopi, E.
• Mucci, M.
• Mattoscio, D.
• Pecce, R.
• Protasi, F.
• Mall, M. A.
• Romano, M.
• Recchiuti, A.